Louis G Lange - Net Worth and Insider Trading
Louis G Lange Net Worth
The estimated net worth of Louis G Lange is at least $20 Million dollars as of 2024-09-20. Louis G Lange is the Director of Audentes Therapeutics Inc and owns about 315,375 shares of Audentes Therapeutics Inc (BOLD) stock worth over $19 Million. Louis G Lange is the Director of NewAmsterdam Pharma Co NV and owns about 24,878 shares of NewAmsterdam Pharma Co NV (NAMS) stock worth over $397,302. Louis G Lange is also the Director of Esperion Therapeutics Inc and owns about 215,517 shares of Esperion Therapeutics Inc (ESPR) stock worth over $363,146. Details can be seen in Louis G Lange's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Louis G Lange has not made any transactions after 2024-02-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Louis G Lange
Louis G Lange Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Louis G Lange owns 7 companies in total, including Audentes Therapeutics Inc (BOLD) , CymaBay Therapeutics Inc (CBAY) , and Esperion Therapeutics Inc (ESPR) among others .
Click here to see the complete history of Louis G Lange’s form 4 insider trades.
Insider Ownership Summary of Louis G Lange
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BOLD | Audentes Therapeutics Inc | 2020-01-15 | director |
CBAY | CymaBay Therapeutics Inc | 2013-10-11 | director |
ESPR | Esperion Therapeutics Inc | 2013-07-01 | director |
2009-04-17 | EVP Cardiovascular Therapeutic | ||
2021-12-02 | director | ||
2022-09-16 | director | ||
2022-09-16 | director |
Louis G Lange Latest Holdings Summary
Louis G Lange currently owns a total of 3 stocks. Among these stocks, Louis G Lange owns 315,375 shares of Audentes Therapeutics Inc (BOLD) as of December 23, 2019, with a value of $19 Million and a weighting of 96.13%. Louis G Lange owns 24,878 shares of NewAmsterdam Pharma Co NV (NAMS) as of February 13, 2024, with a value of $397,302 and a weighting of 2.02%. Louis G Lange also owns 215,517 shares of Esperion Therapeutics Inc (ESPR) as of July 1, 2013, with a value of $363,146 and a weighting of 1.85%.
Latest Holdings of Louis G Lange
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
BOLD | Audentes Therapeutics Inc | 2019-12-23 | 315,375 | 59.97 | 18,913,039 |
NAMS | NewAmsterdam Pharma Co NV | 2024-02-13 | 24,878 | 15.97 | 397,302 |
ESPR | Esperion Therapeutics Inc | 2013-07-01 | 215,517 | 1.69 | 363,146 |
Holding Weightings of Louis G Lange
Louis G Lange Form 4 Trading Tracker
According to the SEC Form 4 filings, Louis G Lange has made a total of 2 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Audentes Therapeutics Inc is the sale of 11,000 shares on December 23, 2019, which brought Louis G Lange around $655,600.
According to the SEC Form 4 filings, Louis G Lange has made a total of 1 transactions in NewAmsterdam Pharma Co NV (NAMS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NewAmsterdam Pharma Co NV is the acquisition of 5,000 shares on February 13, 2024, which cost Louis G Lange around $95,000.
According to the SEC Form 4 filings, Louis G Lange has made a total of 0 transactions in Esperion Therapeutics Inc (ESPR) over the past 5 years. The most-recent trade in Esperion Therapeutics Inc is the acquisition of 14,214 shares on July 1, 2013, which cost Louis G Lange around $198,996.
Insider Trading History of Louis G Lange
- 1
Louis G Lange Trading Performance
GuruFocus tracks the stock performance after each of Louis G Lange's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Louis G Lange is 17.87%. GuruFocus also compares Louis G Lange's trading performance to market benchmark return within the same time period. The performance of stocks bought by Louis G Lange within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Louis G Lange's insider trading performs compared to the benchmark.
Performance of Louis G Lange
Louis G Lange Ownership Network
Louis G Lange Owned Company Details
What does Audentes Therapeutics Inc do?
Who are the key executives at Audentes Therapeutics Inc?
Louis G Lange is the director of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .
Audentes Therapeutics Inc (BOLD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Audentes Therapeutics Inc Insider Transactions
Louis G Lange Mailing Address
Above is the net worth, insider trading, and ownership report for Louis G Lange. You might contact Louis G Lange via mailing address: 3172 Porter Drive, Palo Alto Ca 94034.